Background--The relationships between physical activity (PA) and both cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) have predominantly been estimated using categorical measures of PA, masking the shape of the dose-response relationship. In this systematic review and meta-analysis, for the very first time we are able to derive a single continuous PA metric to compare the association between PA and CVD/T2DM, both before and after adjustment for a measure of body weight.
I
nsufficient physical activity (PA) is a key risk factor for noncommunicable diseases such as cardiovascular diseases (CVD), cancer and diabetes mellitus. 1 CVD is the number 1 cause of death globally, with 17.5 million deaths from CVD and 1.5 million deaths from diabetes in 2012, representing 31% and 2.7% of global deaths, respectively. 2, 3 It has been over half a century since the pioneering studies of bus drivers and then longshoremen, which first established the beneficial impact of PA upon CVD risk. 2, 3 More recently, in 2010 the UK Chief Medical Officer Sir Liam Donaldson declared that the benefits of regular PA on health, longevity, and well-being "easily surpass the effectiveness of any drugs or other medical treatment." 4 Current international recommendations for PA are to achieve at least 150 minutes per week of moderate-intensity aerobic PA, or 75 minutes per week of vigorous PA, 5, 6 and a risk reductions after adjusting for body weight and therefore do not allow for an assessment of the independent effect of PA on health outcomes, and at least part of the observed effect is likely to be mediated by maintenance of healthy weight status. The aim of this study was to conduct a systematic review and meta-analysis to draw together the epidemiological studies that assesses the independent association between PA levels and both CVD and type 2 diabetes mellitus (T2DM) outcomes, using a single continuous metric and adjusting for body weight. In order to make comparable results across disease domains, exposure data for physical activity was converted to a common continuous metric of metabolic equivalent of task (MET) hours per week. Although subject to limitations from original studies, this metric allowed us to study results in order to reflect international PA guidelines. More important, it also allowed us to estimate the relative risk (RR) associated with a unit increase in PA at any activity level, and to explore the dose-response relationship between PA and CVD or T2DM outcomes.
Methods Eligibility Criteria
Studies considered for inclusion were prospective cohort studies that measured PA levels where at least 2 of the following domains were measured: leisure, household, active travel, and occupational activity.
Estimates of the RR for incidence of or mortality from CVDs or T2DM in participants free of disease at baseline had to be reported. Studies that provided estimates for total CVD were included under the main CVD incidence/mortality results. Otherwise, any studies that reported individual CVD outcomes, such as heart failure or myocardial infarct (MI), were included in separate meta-analyses.
In addition, the RR had to be adjusted for a measure of body weight (eg, continuous measurements of body weight, body mass index, waist circumference, etc., or binary measures of overweight, obesity, etc.). For consistency, all such measures are referred to as "body weight." If multiple studies measuring the same outcome were published from the same cohort, preference was given to that with the most years of follow-up in the analysis. Studies were excluded if the PA measure was one of fitness, as opposed to a measure of time or volume of PA. Only studies published in English were included.
Search Strategy
Relevant studies were identified by searching electronic databases and supplemented by scanning the reference lists of included studies and relevant systematic reviews. The search was applied to MEDLINE and EMBASE electronic databases for all studies published from January 1981 to March 2014. Key terms, among others, included "physical activity," "cardiovascular diseases," "stroke," "heart diseases," and "mortality." The complete search strategy is attached as supplemental online material.
Study Selection and Data Extraction
Identified titles and abstracts were initially obtained through application of the search strategy, and these were divided equally among 3 authors to be screened for inclusion on the basis of title, with a fourth reviewer cross-checking a 10% sample of exclusion decisions. The abstracts of studies included after the initial screening were then independently assessed by 2 reviewers for inclusion in the review, with discrepancies referred to a third reviewer and resolved through discussion. A single reviewer reviewed full-text articles, with a second reviewer cross-checking undecided cases and a random 10% sample of excluded articles. A single reviewer performed data extraction, with a 10% sample check conducted by a second reviewer. If any discrepancies arose between reviewers, these were referred to a third reviewer for discussion.
outcomes. The PA exposure in each study was converted to MET hours per day above that expended by the baseline group (referred to throughout as the inactive group) in order to quantify the association on a comparable scale.
One MET is defined as 1 kcal/kg and is approximately equivalent to the energy cost of sitting quietly. 14 This unit was chosen because it provided a continuous variable that could be converted to a single RR estimate for a selected change in volume of PA. Conversion to this scale was performed with reference to the Physical Activity Compendium, 14 which was developed for use in epidemiological studies to standardize the assignment of MET intensities in PA questionnaires. If PA exposure estimates were not directly reported in the form of MET hours, the Physical Activity Compendium was used to convert the information provided about the amount of PA conducted to our standard unit to reflect the time and intensity of activity. Any reference to "moderate" PA was assigned a value of 4.5 METs and vigorous activity a value of 6.5 METs, based on World Health Organization recommendations. 5 Using the compendium, it was decided to assign any references to "inactive behavior" a value of 1.5 METs, and "light activity" a value of 2.5 METs, and average body weights of 84 and 71 kg 15 were assigned to men and women, respectively, where no other information was provided by the studies.
The rules for converting physical activity measures to a standard metric of "Additional MET h/day" are listed in Table S2 .
Statistical Analysis
The relationship between RR and PA was assessed using regression analysis for each study individually. In all cases, it was assumed that the relationship between relative risk and MET hours per week followed a 0.25 power transformation (ie, RR=1+b9MET 0.25 , where b is a regression coefficient).
Additional analyses, namely, both linear and log linear associations, and power transformations of 0.375, 0.50, and 0.75 were also conducted to assess the sensitivity of the findings to the method of parameterising the dose-response relationship. The 0.25 power transformation was chosen for the primary outcome measures because it closely models the observed findings from previous studies that the RR for chronic disease falls quickly with a small addition of PA, but further increases of PA produce rapidly diminishing returns. This transformation has previously been used in a metaanalysis of the effect of PA on all-cause mortality 10 using the Alaike's Information Criterion, in order to select the transformation that best fits the data. 16 Additionally, a categorical analysis was conducted, where the dose-response relationship was assessed nonparametrically, as previously conducted by Kelly et al. 13 For this analysis, data lines were grouped into three categories (0.1-12.0; 12.1-29.5; 29.6+ MET h/week) and meta-analyses within these 3 PA categories were conducted. The 3 categories refer to tertiles of data points collected from the studies.
For each meta-analysis where the dose-response relationship is described parametrically, the same doseresponse relationship was assumed for each individual study, and the dose-response parameter was estimated separately for each study. The meta-analysis was then conducted on the dose-response parameter, with an average value of SE from the PA groups included in each study. Using this method, results could be reported at any value of additional PA, and we have chosen to report results for an increase of 11.25 MET h/week-equivalent to moving from inactive behavior to achieving international PA recommendations. The reported results using the primary outcome measures can also be used to determine the modeled association between PA and the health outcome at any level of PA using a method described in Table 1 .
Random-effects meta-analyses were performed, because of the high degree of heterogeneity in the populations under investigation and follow-up time. 17 The heterogeneity between studies in the meta-analyses was assessed using the I 2 statistic. For each health outcome, 2 sets of meta-analyses were conducted using Stata software (version 12; StataCorp LP, College Station, TX): (1) with RRs adjusted for body weight, including all identified studies (primary outcome); (2) with RRs not adjusted for body weight, including only studies where RRs were also available without adjustment for body weight. Here, "RRs adjusted for body weight" were taken from the fully adjusted models reported in the included studies, and "RRs not adjusted for body weight" were taken from the models adjusting for the most covariates without inclusion of a measure of body weight. Funnel plots were analyzed to assess the possibility of small-study or publication bias. A sensitivity analysis was conducted by restricting results to studies that achieved at least 6 of the 8 quality criteria. Metaregression was performed to explore whether heterogeneity in the results could be explained by study-level variables, including achievement of each of the 8 quality criteria, the sex of participants, mean age of participants, presence of active travel, recreational, occupational, and household domains in the PA measurement, mean follow-up years, and geography.
Ethical approval/institutional review board approval was not required.
Results
The initial literature searches produced 16 628 titles. After a review of the titles and abstracts, 329 articles were reviewed in full, as detailed in the study flow chart (Figure 1 ). An additional 8 studies were identified by scanning reference lists of the included studies. The majority of the excluded studies only measured 1 domain of PA or did not adjust for any measure of obesity. Thirty-six studies were included in the final review (listed in Table S3 ), of which 33 contributed to CVD meta-analyses and 3 contributed to the T2DM metaanalyses. Table 2 provides a summary of the results of the metaanalyses for estimates both with and without adjustment for body weight and also displays the total number of data points and incidents for each disease outcome. Five data points had to be excluded from meta-analyses because they pertained to conditions for which we only had 1 result, such as Wattanakit et al., 18 which was the only study to report the PA effect on venous thromboembolism incidence. These studies are listed in Table S4 . In addition, 3 studies were removed in the review stage because of overlapping cohorts. More specifically, Figure 2 graphically outlines RR results for the CVD mortality studies plotted against the amount of PA in our standardized metric.
The 0.25 power transformation is chosen as the preferred transform in this article because demonstrates a better fit to the data; the r 2 value for this transformation was 0.75 compared to 0.29 for the log linear transformation. In terms of the dose-response relationship, the incremental change in risk for 3 differing intensities of PA (low, medium, and high) are listed in Table 3 . In general, we noted that the greatest rate of reduction occurs in the first category, that is, as you move from low to medium amounts of PA rather than from medium to high.
Cardiovascular Disease Meta-Analyses
The 33 studies included in the CVD meta-analyses were conducted in Europe (n=13), the United States (n=13), and the rest of the world (n=7). They included a total of 1 683 693 participants, with 89 493 events occurring during an average follow-up period of 12.8 years. The number of data points pooled for each health outcome was as follows: 5 for CVD incidence, 14 for CVD mortality, and 9 for stroke incidence; 6 for CHD incidence, 2 for CHD mortality, 5 for heart failure incidence, and 2 for MI incidence. Increasing PA by 11.25 MET h/week was associated with a significant decrease in risk for all of the cardiovascular outcomes. The protective association for CVD mortality (RR, 0.77) was greater than for CVD incidence (RR, 0.83), a result that was also shown when restricting both meta-analyses to studies that reported results for both CVD mortality and incidence. Figure 3 displays the meta-analysis of the effect of PA on CVD mortality after adjustment for body weight for the included studies. The meta-analyses for the remaining conditions are shown in Figures S1 through S7.
The results that were adjusted for body weight were only slightly attenuated in comparison with the results that were not adjusted for body weight. The greatest effect of body weight adjustment was noted in the RR of CVD mortality, which reduced from 0.66 (unadjusted) to 0.77 (adjusted for body weight).
The meta-analysis results for the various subcategories of CVD outcomes (such as MI incidence) showed that the estimated RRs were very similar to CVD as a whole. The 0.25 power transformation for overall CVD incidence was 0.83, versus 0.82 for stroke incidence, 0.80 for CHD incidence, 0.81 for heart failure incidence, and 0.75 for MI incidence. The dose-response graphs ( Figures S8 and S9) show that the greatest risk reduction was observed when moving from 
This can then be used to estimate the RR for a unit increase of MET h/day at any PA level. For example, the RR of CVD incidence associated with a change from 2 to 5 MET h/day is estimated as follows:
inactive to moderate PA. Therefore, one can extrapolate that the greatest benefit may be derived from an additional 6 MET h/week, with a risk reduction of %4.3% per MET h/ week for CVD mortality and 1.7% for CVD incidence, respectively.
Type 2 Diabetes Mellitus
Three studies were identified with incidence of T2DM as an outcome variable. These 3 studies were conducted in the UK, United States, and China, respectively. They included a total of 261 618 participants and 19 417 events occurring during an average follow-up period of 7.5 years.
The meta-analysis found a 0.74 RR (95% CI, 0.77-0.72) for T2DM after adjustment for body weight and a marginally greater reduction in risk in models not adjusted for body weight.
The dose-response curve shown in Figure S10 demonstrates that the largest benefit may be derived when moving from inactive (0 METs) to 6 METs (RR, 0.77), compared with 0.74 in response to 11.25 MET h/week of PA as per current guidelines.
Sensitivity Analysis
For T2DM, CVD mortality, and CVD incidence, the results of the meta-analysis were robust to the method of parameterizing the dose-response relationship (Table 4 ). In general, the results obtained using the selected 0.25 transformation were similar to those obtained using other transformation for each of the disease outcomes, including both linear and log linear relationships. For CVD incidence, CVD mortality, stroke incidence, CHD incidence, CHD mortality, heart failure incidence, and MI incidence, the 0.25 power transformation produced the result furthest from the null hypothesis. For instance, in estimating the RR of CVD incidence for an Estimates of relative risk for CHD incidence and heart failure incidence were more sensitive to the choice of parameterization, with results for CHD incidence ranging from RR 0.80 (0.25 power transformation) to 0.90 (linear relationship). Table S5 demonstrates the effects of limiting the metaanalyses to those studies that achieved at least 6 of the 8 quality criteria. This restriction made very little difference to the results, with a slight increase in the observed RR reduction associated with an 11.25 MET h/week increase in PA for the vast majority of disease outcomes. Interestingly, for CHD incidence, the RR reduction attenuated slightly from 0.23 to 0.19 when including only the higher-quality studies. As expected, however, there was some sensitivity when the quality criterion was used as a continuous measure, in that the verylow-quality studies overestimated the impact of PA on health.
A further sensitivity analysis was conducted to exclude studies with PA levels that were deemed implausible (ie, PA levels that were excessively high or low). The thresholds for implausibility were PA levels exceeding 10 times the recommendations, or lower than 30 minutes of PA per week, respectively (a level too low to be accurately measured by questionnaire). For CVD mortality, only 3 of 17 studies exceeded the maximum threshold, and only 1 study was under the minimum threshold (ie, recommended PA levels of 11.25 METs; Figure S11 ). However, Table S5 demonstrates that repeating the analysis without these implausible studies made negligible difference to the overall results. The highest level of PA in most CVD studies was around 2 to 3 times the recommended 11.25 MET h/week ( Figure S12 ). The T2DM studies all had plausible PA-level ranges, as demonstrated in Figure S13 . The highest exposure category had PA levels varying from 8.25 to 13.8 METs, corresponding well to the recommended PA levels of 11.25 METs/week. The various power transformations, namely, both linear and log linear associations, as well as power transformations of 0.25, 0.375, 0.50, and 0.75, are presented in Table 4 for the various outcomes. CHD indicates coronary heart disease; CVD, cardiovascular disease; ICD, International Classification of Disease; MI, myocardial infarction; RR, relative risk; n/a, too few studies for a meta-analysis; T2DM, type 2 diabetes mellitus. 
Heterogeneity and Assessment of Bias
Heterogeneity was demonstrated through the I 2 statistics and examination of both the forest and funnel plots. Table 2 demonstrated significant heterogeneity in the study results for CVD and CHD mortality, which may well be a consequence of the varying populations with differing baseline measures of PA and varying methods of measurement. Of note, however, inclusion of body-weight-adjusted studies did reduce the I 2 statistics throughout. Relative risk for CVD mortality of increase of 11.25 MET h/w Meta-Regression Table S6 shows the effects of moderator variables on the RR of CVD mortality. First, there was an association between quality of study and effect size, with a metaregression coefficient of 0.07 per quality score point. In addition, it was noted that studies that measure body weight using subjective measurements estimate a 0.24 lower RR as compared with those that use objective measurements. In assessing the effects of geographical location, US cohort studies estimated an RR further from the null hypothesis, with a difference of %0.15, as compared with studies conducted elsewhere.
Small Study Bias or Publication Bias
Small study effects, or publication bias, was assessed through visual inspection of the funnel plots, as shown in Figure 4 for CVD mortality (the remaining conditions displayed in Figures S14 through S20 ). In general, the plots were highly symmetrical, showing little signs of publication bias. In certain disease outcomes, the smaller, less-powerful studies often overestimated the effects of PA. For example, in CVD incidence, the Framingham male cohort, which contributed a mere 0.4% weighting provided an RR estimate of 0.53 as compared with the overall estimated relative of CVD incidence of 0.83. In contrast, however, for CHD incidence, the smallest study reported an increase in disease outcome for increasing PA levels. The Belstress men's cohort, 21 which was afforded a weighting of 0.50% reported an RR of 1.12 compared with the overall RR estimate of 0.80 for CHD incidence. These data points highlighted the effect of small study bias, which could be attributed to clinical or methodological diversity.
Discussion
We found a decrease in the risk of all cardiovascular outcomes and diabetes mellitus incidence with increasing levels of PA. These RRs were only marginally attenuated when adjusting for a measure of body weight, suggesting that the majority of the health benefit that accrues from increasing PA is mediated by mechanisms beyond weight maintenance. Our findings suggest that an increase in 11.25 MET h/week for an inactive individual is associated with a reduction of risk for cardiovascular mortality by 23% and diabetes mellitus incidence by 26%, independent of body weight. This may 
however, the key benefit of this article is that the results can be generated for an MET value, including 7.5 to provide a direct comparison.
Strengths and Weaknesses
This is the first meta-analysis to assess the effect of PA on CVD and diabetes mellitus using a continuous index of PA, thereby allowing for direct comparison of results across studies with heterogeneous data collection methods. Previous meta-analyses that have considered the effect of PA on health outcomes have mostly used categorical measures of PA (eg, high vs moderate vs low). [23] [24] [25] Those that used a single continuous comparable index of PA have not considered multiple health outcomes. 10, [26] [27] [28] This study is the first to consider a range of CVDs simultaneously, allowing for comparable results across these disease boundaries.
The results of these meta-analyses, which can be used to estimate the risk reduction associated with a unit increase of PA at any PA level, are vital for an accurate assessment of the population burden of physical inactivity. A recent study estimated the global burden of physical inactivity and concluded that the population health burden associated with physical inactivity was of an equivalent size to that associated with smoking. 29 However, this analysis has been criticized for overestimating the burden of PA, 30 given that the researchers derived their population impact fractions (PIFs) for physical inactivity from RRs drawn from meta-analyses that either compare pooled estimates of "low" PA with "high" PA, or compare inactive behavior with meeting PA recommendations (although other assumptions by the authors are likely to result in underestimation). 29 The appropriate RRs for such PIFs should compare PA at the average level within the inactive population with the level required to meet recommendations. Such RRs can only be derived from analyses similar to those reported here, which account for the continuous nature of the PA variable.
Our results supported the assumption of other metaanalysis that the inactive have most to gain by any increase in PA. The relationship between PA and health outcomes is such that a small increase from inactive behavior provides most of the benefit, and subsequent increases produce diminishing returns. This is supported by 2 previous meta-analyses that assessed the dose-response relationship between PA and coronary heart disease 26 and all-cause mortality. 10 The
Woodcock meta-analysis suggested that a first-degree fractional polynomial with 0.25 power (as has been used in this study) provides the best fit to the data. 10 However, a drawback of using such a transformation is that it is necessary to set a somewhat arbitrary "zero" level of PA. We assumed that the reference group from each of the studies achieved zero PA (ie, they were considered to be inactive), but the actual PA level in these groups will vary between studies. The fact that the included studies tended to show the same "diminishing returns" relationship with PA suggests that the levels of PA in the reference groups were fairly similar and approximately sedentary. However, this diminishing returns relationship could be evidence of a general bias present in the studies inflating the risk of disease in the PA reference groups. We explored the effect on meta-analysis results of method of parameterizing the doseresponse relationship and also compared results with nonparametric categorical analyses and, in most cases, found that the results were robust to choice of method. A limitation of using the comparable index of PA is that it does not distinguish between sustained periods of moderate activity and short periods of vigorous activity, which may have differing effects on health. Also, the PA recommendations 6 advise either 150 minutes of moderate-to-vigorous activity (150 MVPA) or 75 minutes of vigorous physical activity (75 VPA), whereas in this analysis we have focused on the more commonly used 150 MVPA. Therefore, our results pertain to 11.25 MET h/week, whereas for 75 VPA (with 6.5 METs for vigorous activity), the results would be presented for 9.75 MET h/week; therefore, this would attenuate the RR estimates. With respect to the search strategy, the potential of introducing bias into the review process by use of a single reviewer for reviewing full-text articles and for the data extraction process cannot be excluded, although a second reviewer cross-checked undecided cases and a 10% sample was checked by another reviewer at each stage of assessment.
The aim of this article was to explore the effect of total PA, expressed as metabolic expenditure, as opposed to domainspecific investigation. In reality, although many studies use a combination of domains to estimate total PA, they rarely truly include measurement of total PA exposure. We decided to include studies that had assessed 2 or more (of the 4 main) domains because this is likely to represent a reasonable minimum to be able to assess a meaningful proportion of overall PA exposure.
The studies included in this systematic review were mostly of high quality, notwithstanding the variability in PA measures. The prospective cohort study design provides some protection against recall or selection bias. There were few issues with loss to follow-up or with detection of events. However, the measures of PA used in the studies were heterogeneous, both in terms of the measurement tools and in the aspects of PA that were being measured. As a result, the derivation of the comparable index of PA was challenging and is likely to have included some misclassification bias, because we were forced to make assumptions about behavior and activity levels that were not reported in the studies. Usually, misclassification bias would result in an underestimate of effect size, but here it may have led to a reduction in variance in PA levels, which will have led to a general bias away from the null hypothesis for the studies included in the meta-analysis.
It has previously been noted that studies of the effect of PA on health would benefit from improved measures of nonleisure time PA, particularly for studying the effect in women where levels of recreational activity are lower. 24 The use of self-reported PA questionnaires in all of the included studies is problematic, given that self-reported PA has been shown to have a low-to-moderate correlation with objective measures. 31 Furthermore, whereas all of the studies used healthy participants, only half included a "burn-out" period to reduce the risk of reverse causation. The lack of availability of studies conducted in low-and middle-income countries precludes our ability to assess the impact of increasing PA levels in these settings, where the burden of physical inactivity and noncommunicable diseases is also high. Given that all of the studies included in the meta-analysis were observational, the potential for residual confounding from imprecise or unmeasured factors cannot be excluded from pooling. Although all of the studies adjusted for multiple potential confounding variables, not all confounders were adjusted for in every study. Similarly, all of the results included in the meta-analysis were based on analyses using measures of PA and body weight made at only 1 time point, which is likely to result in underestimates of the effect of PA on health.
Comparison With Other Studies
Three other reviews investigating the effects of PA on CVD are summarized in Table 5 .
11,22-24,32
Each review had different objectives and used different methods both to identify studies and combine results. The majority have chosen to combine risk estimates based on categorical measures of the exposure variable. We believe that our point estimates for the RR associated with CVD outcomes (increasing PA by 11.25 MET h/week) correspond most closely with comparisons between moderate and low levels of PA. Our estimated RR of 0.83 for congestive heart disease incidence is similar to estimates from meta-analyses by Sofi et al. 33 and Oguma et al., 23 whereas our estimate for stroke incidence is of greater magnitude than that by Diep et al. 24 Our estimate for T2DM incidence is similar to that produced by Jeon et al.
11
Our study results for CVD mortality also proved similar to Arem et al., 22 which fell outside our search dates but was added later at the review stage. Arem et al. studied the effects of leisure time PA on all-cause and also CVD mortality and found a CVD mortality hazard ratio of 0.80 between 0.1 and 7.5 METs and 0.67 corresponding to 7.5 to 15 METs of leisure time PA. These estimates correspond extremely well with our estimates for CVD mortality at 11.25 METs, although the main focus of the Arem et al. article was to explore the potentially harmful effects of extremely high PA levels, up to 75 MET h/week.
Conclusions
This meta-analysis has provided an assessment of the health benefits for a unit increase in PA levels, both before and after adjustment for body weight. The methods used here enable direct comparison of the effect of PA on a range of CVDs and diabetes mellitus. Future studies should investigate the effect of increasing PA levels in low-and middle-income countries. Further analysis of the effect of increasing PA on other health 
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Disclosures
None.  Selection of non-exposed (0 = no description or drawn from different source than exposed, 1 = otherwise) The single metric that we converted all the measures from the identified papers to was 'Additional MET hours per day' (or 'Additional METh/d'). This measure is a comparative measure, where the baseline group in each paper is arbitrarily assigned the value of zero and the extra physical activity in the other exposure groups is estimated as the amount of time spent in physical activity multiplied by the intensity of the physical activity, measured in METs (or 'metabolic equivalents'). METs are a standard measure used in physical activity research, which are an estimate of the intensity of physical activity compared to a baseline of 1 MET which is the intensity of sitting quietly. A standard compendium of MET values for many different activities can be found on the Compendium of Physical Activities Google Site. (34) In order to develop the 'Additional METh/d' metric, it is necessary to estimate the METh/d for all of the reported physical activities described in each paper for each of the exposure groups, and then subtract the baseline METh/d from each of the groups. There were a number of standard rules that we applied for each paper, to remove subjectivity from the process. These rules were as follows:
1. When a paper uses a range to describe an exposure (e.g. 0-2 h/week walking) we used a point estimate which was the mid-point of the range. 2. When a paper uses an open category to describe an exposure we assume that the size of this category is the same as the closest equivalent exposure category and then calculate the median. For example, if a paper categorised walking as 0-2h/week; 2-4h/week; 4+ h/week, then we assume that the last exposure group is 4-6h/week and use the median value of 5h/week. 3. When physical activity is measured in 'occasions' or 'sessions' but no time is estimated, we assume that each occasion or session is half an hour. 4. When a paper describes physical activity in terms of intensity (rather than describing the actual activity that was performed) then we assume the following MET values: light intensity: 2.5 METs; moderate intensity: 4.5 METs; vigorous intensity: 6.5 METs. Ambiguous activities are assigned to either light, moderate or vigorous intensity levels -for example, 'exercise' or 'sport' are both categorised as vigorous. 5. Where the paper tries to measure amount of time spent in 'moderate or vigorous' physical activity but gives no information about the type of activity, we assume a MET value of 5.5. 6. Often papers categorised groups using an 'or' function. For example, an exposure group may consist of individuals who walk for at least 5 hours per week or exercise for at least two hours per week. In these instances, we assumed that any combination of these two activities is equally likely. So we calculated the METh/d for someone who only walks 5 hours per week, for someone who only exercises for two hours a week, and for someone who both walks for five hours a week AND exercises for two hours a week. We then calculated the average of the three measures, and assigned that value to the exposure group. 7. When a paper split groups into x-tiles of an exposure variable and provided estimates of mean and standard deviation of the exposure variable in the whole sample, we assumed that the exposure variable was log-normally distributed (unless otherwise stated in the paper) and then calculate the exposure variable for each of the x-tile variables from this assumed distribution. 
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